Company Overview and News
SEOUL, Oct. 14 (Yonhap) -- Hyundai Motor Co., South Korea's biggest carmaker by sales, said Sunday that it aims to ship 5,000 hydrogen fuel cell electric vehicles to France by 2025.
HYUO HYUP AI HYUD
La Motte-Fanjas, le 25 septembre 2018 - 17h45 - McPhy (Euronext Paris Compartiment C : MCPHY, FR0011742329) spécialiste des équipements de production, stockage et distribution d'hydrogène, annonce aujourd'hui son premier contrat pour une station hydrogène 700 bar avec H2 Mobilité Allemagne avec une mise en service prévue à Berlin sur le dernier trimestre 2019.
La Motte-Fanjas, September 25, 2018 - 5:45 p.m. - McPhy (Euronext Paris Compartment C: MCPHY, FR0011742329), a specialist in hydrogen production, storage and distribution equipment, today announces its first contract for a 700 bar hydrogen station with H2 Mobility Deutschland, which is due to enter service in Berlin during the last quarter of 2019.
SAN FRANCISCO, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a leading provider of energy solutions that change the way the world moves, today elaborates on its participation in the Hydrogen Council’s 3rd Annual CEO Event, this year entitled The Global Hydrogen Leaders Forum, at the 2018 Global Climate Action Summit in San Francisco. Today, Plug Power CEO Andy Marsh will speak alongside fellow CEO representatives of the Hydrogen Council, covering how hydrogen can address future energy challenges, as well as reviewing the progress the industry has made over the past year.
On Aug 27, we issued an updated research report on Lincoln Electric Holdings, Inc. (LECO - Free Report) . The company is poised to gain from its focus on product innovation, integration of the Air Liquide acquisition, along with execution of the 2020 vision and strategy. Nevertheless, raw material inflation, tariffs and a softer energy business might impede the company’s near-term growth. Let’s illustrate the factors in detail.
REGN GWW ATKR IRBT LECO AI
FRANKFURT/MUNICH (Aug 22): Linde warned that divestments needed to secure approval for its planned tie-up with Praxair have reached a size that would allow either party to abandon the deal, but added it was in constructive talks to salvage the US$83 billion merger.
FRANKFURT/MUNICH (Reuters) - Linde (LIN1.DE) warned that divestments needed to secure approval for its planned tie-up with Praxair (PX.N) have reached a size that would allow either party to abandon the deal, but added it was in constructive talks to salvage the $83 billion merger.
The EU on Monday cleared the merger of German industrial gas giant Linde and US-based Praxair after the two firms made a concession to Brussels competition authorities.
BRUSSELS (Aug 20): German industrial gases group Linde and U.S. rival Praxair secured conditional EU antitrust approval on Monday for their US$82 billion merger, but still have to clear a major hurdle with U.S. enforcers.
BRUSSELS (Reuters) - EU antitrust regulators approved on Monday German industrial gases group Linde’s (LING.DE) planned $82 billion merger with U.S. rival Praxair (PX.N) after the companies agreed to sell Praxair’s assets to a Japanese rival together with other concessions.
BRUSSELS, Aug 20 (Reuters) - EU antitrust regulators approved on Monday German industrial gases group Linde’s planned $82 billion merger with U.S. rival Praxair after the companies agreed to sell Praxair’s assets to a Japanese rival together with other concessions.
Several large European companies are among those impacted by renewed American sanctions on Iran, following Donald Trump’s announcement that the US was pulling out of the international deal to contain Tehran’s nuclear programme.
SMIZY SMIZF AI
Shares in Linde plunged more than 8 percent on Monday after the industrial gases group's planned US$87 billion merger with Praxair was put in doubt by demands from U.S. antitrust regulators.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to EPA:AI / AIR LIQUIDE on message board site Silicon Investor.